We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+26.76%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.78B
AUM Growth
+$199M
Cap. Flow
-$18.8M
Cap. Flow %
-1.06%
Top 10 Hldgs %
47.19%
Holding
82
New
6
Increased
3
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$38.6M
2
VERU icon
Veru
VERU
+$36.1M
3
EXEL icon
Exelixis
EXEL
+$24.2M
4
VTYX
Ventyx Biosciences
VTYX
+$18.8M
5
GOSS icon
Gossamer Bio
GOSS
+$13.8M

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$42.9M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$37.1M
3
BPMC
Blueprint Medicines
BPMC
+$14.9M
4
BMEA icon
Biomea Fusion
BMEA
+$14.2M
5
NUVB icon
Nuvation Bio
NUVB
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.33%
2 Financials 0.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$140M 7.86%
2,000,000
– –
CYTK icon
2
Cytokinetics
CYTK
$10.5B
$102M 5.72%
2,100,000
– –
RXDX
3
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$101M 5.69%
1,714,000
– –
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
$97.6M 5.49%
3,421,541
+1,345,636
+65% +$38.6M
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$89M 5.01%
1,303,700
– –
RVMD icon
6
Revolution Medicines
RVMD
$39.9B
$78.6M 4.42%
3,984,264
+500,000
+14% +$11M
ONC
7
BeOne Medicines Ltd
ONC
$32.8B
$67.4M 3.79%
500,000
– –
AMLX icon
8
Amylyx Pharmaceuticals
AMLX
$2.26B
$58.7M 3.3%
2,084,000
-116,000
-5% -$2.89M
TYRA icon
9
Tyra Biosciences
TYRA
$1.9B
$56.7M 3.19%
6,448,359
– –
RLAY icon
10
Relay Therapeutics
RLAY
$4.1B
$48.5M 2.73%
2,169,132
-500,000
-19% -$11M
SAGE
11
DELISTED
Sage Therapeutics
SAGE
$42.8M 2.41%
1,094,000
– –
GOSS icon
12
Gossamer Bio
GOSS
$82.9M
$42.8M 2.41%
3,571,928
+1,109,570
+45% +$13.8M
ITOS
13
DELISTED
iTeos Therapeutics
ITOS
$41M 2.31%
2,154,058
– –
MRUS
14
DELISTED
Merus
MRUS
$38.1M 2.14%
1,900,000
– –
PMVP icon
15
PMV Pharmaceuticals
PMVP
$59.2M
$37.6M 2.12%
3,163,795
-334,841
-10% -$4.84M
RCUS icon
16
Arcus Biosciences
RCUS
$3.55B
$37.5M 2.11%
1,432,200
– –
BLU
17
DELISTED
BELLUS Health Inc.
BLU
$33.8M 1.9%
3,200,000
– –
ANAB icon
18
AnaptysBio
ANAB
$1.58B
$33.2M 1.87%
1,300,000
– –
IDYA icon
19
IDEAYA Biosciences
IDYA
$3.42B
$32.9M 1.85%
2,202,812
– –
RETA
20
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$31.1M 1.75%
1,239,000
– –
VTYX
21
DELISTED
Ventyx Biosciences
VTYX
$29.7M 1.67%
+850,000
New +$18.8M
VERU icon
22
Veru
VERU
$36M
$28.8M 1.62%
+250,000
New +$36.1M
AKRO
23
DELISTED
Akero Therapeutics
AKRO
$28.3M 1.59%
831,495
– –
TNGX icon
24
Tango Therapeutics
TNGX
$4.43B
$24.9M 1.4%
6,871,642
– –
FOLD
25
DELISTED
Amicus Therapeutics
FOLD
$24.3M 1.37%
2,325,000
– –
1
2 3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Boxer Capital held 82 positions worth $1.78B, up 13% from $1.58B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Boxer Capital's Q3 2022 filing shows 6 new, 3 increased, 8 reduced and 9 closed positions. Its largest new stake was Veru: 250,000 shares worth $28.8M. The largest sale was Turning Point Therapeutics, Inc. Common Stock, an estimated $42.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q3 2022 buy was Veru: 250,000 shares worth $28.8M.
  • Boxer Capital added most to SpringWorks Therapeutics in Q3 2022, an estimated $38.6M increase.
  • Boxer Capital's biggest Q3 2022 reduction was Blueprint Medicines, cutting an estimated $14.9M.
  • Boxer Capital fully exited Turning Point Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $42.9M.
  • Boxer Capital's ten largest holdings make up 47% of its $1.78B portfolio in Q3 2022.
  • Boxer Capital opened 6 new positions and closed 9 in Q3 2022.
  • Boxer Capital's portfolio value rose 13% quarter-over-quarter to $1.78B.

Based on Boxer Capital's 13F filing for Q3 2022, filed 14 Nov 2022.